We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Potential Drug Candidate Blocks Alternate DNA Repair Route in BRCA-Mutated Cancer Cells

By LabMedica International staff writers
Posted on 22 Nov 2015
Print article
Image: Ring structure of the RAD52 protein (Photo courtesy of Wikimedia Commons).
Image: Ring structure of the RAD52 protein (Photo courtesy of Wikimedia Commons).
Image: Structure of 6-hydroxy-DL-dopa (6-OH-dopa) (Photo courtesy of the [US] National Institutes of Health).
Image: Structure of 6-hydroxy-DL-dopa (6-OH-dopa) (Photo courtesy of the [US] National Institutes of Health).
Cancer researchers have identified a low molecular weight compound that inhibits the RAD52 DNA repair protein and kills cancer cells with a BRCA mutation by blocking the alternate DNA repair route.

BRCA2 and BRCA1 are normally expressed in the cells of breast and other tissues, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer as well as for ovarian, prostate, pancreatic, and other cancers.

The protein product of the RAD52 (RAD52 homolog, DNA repair protein) gene binds single-stranded DNA ends, and mediates the DNA-DNA interaction necessary for the annealing of complementary DNA strands. It had been shown in earlier studies that suppression of RAD52 caused the death of BRCA-deficient cells. However, drugs capable of blocking RAD52 had not been identified.

To find a RAD52 inhibitor, investigators at Temple University (Philadelphia, PA, USA) screened more than 18,000 compounds. Eventually they identified 6-hydroxy-DL-dopa (6-OH-dopa) as the only small molecule (molecular weight 213.2) that consistently prevented RAD52 from binding to single-stranded DNA.

The investigators reported in the November 5, 2015, online edition of the journal Chemistry & Biology that multiple molecules of 6-OH-dopa bound to and completely transformed RAD52 undecamer rings into dimers, which abolished the ssDNA binding channel observed in crystal structures. In vitro experiments showed that 6-OH-dopa selectively inhibited the proliferation of BRCA-deficient cancer cells, including those obtained from leukemia patients. Normal cells with functioning BRCA were not affected by inhibition of RAD52.

"Every cell has redundant DNA repair pathways," said senior author Dr. Richard T. Pomerantz, assistant professor of medical genetics and molecular biochemistry at Temple University. "If the main DNA repair pathway, BRCA-mediated homologous recombination, becomes defective cancer cells adapt and still proliferate. The effect is like knocking out two legs of a table that normally is supported by four legs. One leg is lost to BRCA mutations and another to RAD52 inhibition. With only two legs left, the table collapses. Normal cells are left on three legs, due to only RAD52 inhibition, so they survive."

Related Links:

Temple University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.